首页>投融资
Adaptilens
A轮
Adaptilens的使命是将一种模拟人类晶状体的调节式人工晶状体推向市场，让患者无需戴眼镜或隐形眼镜也能拥有出色的近距离视力。Adaptilens的仿生设计最接近人体的自然晶状体。Adaptilens可以让眼睛内的睫状肌改变晶状体的形状，使眼睛在观看近处的物体时能够自然地适应和清晰地聚焦。当眼睛聚焦在远处的物体上时，自适应镜会回到它的基准椭圆形状，让眼睛在远处看得更清楚。
基本信息
-
公司全称Adaptilens Inc
-
类型人工晶状体研发商
-
产业领域医疗器械、治疗设备
-
公司人数15~50人
-
地址
-
联系电话
-
邮箱lianeclamen@adaptilens.com
-
成立时间2019-01-01
投融资
-
2024-04-29A轮1750万美元Perceptive AdvisorsPillar VC380 CapAccanto Partners
-
2020-11-12种子轮160万美元Pillar VCAccanto Partners
相关投融资企业
C轮
Francis Medical is a dynamic medical device company committed to developing urological cancer treatments that are tough on cancer yet gentle on patients.In September 2020, Coloplast announced that it has completed a USD 4m (DKK 25m) equity investment in Francis Medical
收并购
Gynesonics is a developer of transcervical, uterus-preserving, incision-free technologies for diagnostic and therapeutic applications (avoiding invasive surgical techniques of hysterectomy or myomectomy for symptomatic uterine fibroids). Products include the Sonata system which combines intrauterine ultrasound guidance with targeted radiofrequency ablation.In April 2023, the company closed a financing round of $25M
未公开
BetaGlue Therapeutics是一家临床分期肿瘤公司，该公司开发了一种先进的放疗平台，能够对不可切除的实体瘤和手术切缘进行局部靶向治疗，称为YntraDose。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息